# EDGAR Filing Document

**Accession Number:** 0001106838
**File Stem:** 0001493152-23-003665
**Filing Date:** 2023-2
**Character Count:** 3101
**Document Hash:** 3e0370d4b1181a144a33b739d41c154a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-003665.hdr.sgml**: 20230308

**ACCESSION NUMBER**: 0001493152-23-003665

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230206

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sonnet BioTherapeutics Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001106838
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 522102141
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 100 OVERLOOK CENTER
- **STREET 2:** SUITE 102
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540
- **BUSINESS PHONE:** 609-375-2227

**MAIL ADDRESS:**
- **STREET 1:** 100 OVERLOOK CENTER
- **STREET 2:** SUITE 102
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Chanticleer Holdings, Inc.
- **DATE OF NAME CHANGE:** 20050510

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TULVINE SYSTEMS INC
- **DATE OF NAME CHANGE:** 20000214

CHARDAN CAPITAL MARKETS, LLC

17 State Street, Suite 2100

New York, NY 10004

February 6, 2023

<u>VIA EDGAR</u>

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, DC 20549

Attention: Cindy Polynice

---

| | |
|:---|:---|
| Re: | Sonnet BioTherapeutics Holdings, Inc. |
|  | Registration Statement on Form S-1, File No. 333-269307 |
|  | REQUEST FOR ACCELERATION OF EFFECTIVENESS |

---

Requested Date: February 7, 2023 <br> Requested Time: 5:00 p.m., Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), we, as representative of the underwriters of the proposed public offering of securities of Sonnet BioTherapeutics Holdings, Inc. (the "<u>Company</u>"), hereby join the Company's request that the effective date and time of the above-referenced registration statement on Form S-1 be accelerated so that it will be declared and become effective at 5:00 p.m., Eastern Time, on February 7, 2023, or as soon thereafter as possible.

Pursuant to Rule 460 under the Securities Act, we, as representative of the underwriters, wish to advise you that there will be distributed to each underwriter, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

The undersigned advises that it has complied and will continue to comply, and that it has been informed by the participating underwriters and dealers that they have complied with and will continue to comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| CHARDAN CAPITAL MARKETS, LLC | CHARDAN CAPITAL MARKETS, LLC |
| By: | */s/ Shai Gerson* |
| Name: | Shai Gerson |
| Title: | Managing Director |

---